Mirtazapin Actavis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Actavis, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It treats major depressive disorder in adults.

GNH USA supplies Mirtazapin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used to treat depressive disorders by modulating noradrenergic and serotonergic neurotransmission.

- Major depressive disorder: reduces depressive symptoms and improves sleep and overall mood. - Depressive episodes in bipolar disorder (adjunct): helps alleviate the depressive phase when prescribed by a specialist. - Anxiety associated with depression: may lessen anxiety symptoms in patients with co‑existing depressive illness.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Somnolence

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior, especially early in treatment - Severe hypotension - Seizures - Hepatic dysfunction

Before prescribing Mirtazapine, clinicians should consider several safety factors.

- Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown excretion; consider alternative therapy. - Elderly: increased sensitivity to sedation and risk of falls. - Concomitant CNS depressants: may enhance sedative effects. - Alcohol: avoid as it can intensify CNS depression. - Store at room temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Alcohol: enhances CNS depression. - Antihistamines: additive sedation. - Carbamazepine or phenytoin: may reduce mirtazapine effectiveness. - Warfarin: possible alteration of INR. - Benzodiazepines: increased sedative effect.